scispace - formally typeset
Open AccessJournal ArticleDOI

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope

Reads0
Chats0
TLDR
In this article , the authors introduce the types of non-small molecule PROTACs, describe the advantages of NSM-PROTACs and summarize the development of NMT-PROPACs so far in detail.
About
This article is published in Acta Pharmaceutica Sinica B.The article was published on 2022-02-01 and is currently open access. It has received 7 citations till now. The article focuses on the topics: Medicine.

read more

Citations
More filters
Journal ArticleDOI

Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.

TL;DR: This work will summarize the latest development of representative PROTACs focusing on research mainly in past 10 years and discuss their advantages and disadvantages, as well as the outlook and perspectives on the associated challenges and future directions.
Journal ArticleDOI

Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy.

TL;DR: In this paper , a bio-orthogonal reaction-driven self-assembly strategy was proposed to improve the degradation performance of PROTACs in living cells, and the results demonstrated that a highly specific bio-on-off reaction driven intracellular selfassembly strategy could be utilized to improve degradation performance.
Journal ArticleDOI

Construction of lncRNA- and circRNA-associated ceRNA networks in the prostatic urethra of rats after simulating transurethral laser prostatectomy (TULP).

TL;DR: Wang et al. as mentioned in this paper constructed the lncRNA- and circRNA-associated ceRNA regulatory networks related to wound repair after TULP in rats, and provided theoretical support for the repair of post-prostatectomy wound.
Journal ArticleDOI

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.

TL;DR: In this paper , the authors summarized the cutting-edge advances of the stimuli-activatable PROTAC prodrugs and discussed the progress of PROTAC-based nanomedicine to improve PROTAC delivery to the tumors and precise POI degradation in the targeted cells.
Journal ArticleDOI

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.

TL;DR: The current status of E3 ligases and corresponding ligands for PROTACs design with a focus on their discovery history, design principles, application benefits, and potential defects are summarized in this paper .
References
More filters
Journal ArticleDOI

Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer

TL;DR: In this article, the authors used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression and identified recurrent gene fusions of the 5' untranslated region of TMPRSS2 to ERG or ETV1.
Journal ArticleDOI

Peptide therapeutics: current status and future directions.

TL;DR: The current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development are discussed.
Journal ArticleDOI

The Human Transcription Factors.

TL;DR: This review considers how TFs are identified and functionally characterized, principally through the lens of a catalog of over 1,600 likely human TFs and binding motifs for two-thirds of them, highlighting the importance of continued effort to understand TF-mediated gene regulation.
Journal ArticleDOI

HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein Analysis

TL;DR: The utility of this modular protein tagging system for cellular imaging and protein immobilization is demonstrated by analyzing multiple molecular processes associated with NF-kappaB-mediated cellular physiology, including imaging of subcellular protein translocation and capture of protein--protein and protein--DNA complexes.
Journal ArticleDOI

Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy

TL;DR: It is found that wild-type α-synuclein was selectively translocated into lysosomes for degradation by the chaperone-mediated autophagy pathway, which may underlie the toxic gain-of-function by the A53T and A30P mutants.
Trending Questions (1)
What PROTACs are approved by FDA?

The text does not provide information about any specific PROTACs that have been approved by the FDA.